Drugs / Favipiravir
Favipiravir
Trials 49 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT06024421 | May 2024 → Jun 2027 expected | infectious disease | French National Institute of Health and Medical Research | Recruiting | No outcome recorded |
| Phase 1 | NCT01419457 | Aug 2011 → Feb 2013 | — | MDVI, LLC | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT04746183 | Jul 2020 → Mar 2027 expected | COVID-19 | University of Liverpool | Recruiting | No outcome recorded |
| Phase 1/2 | NCT01728753 | Nov 2012 → Feb 2013 | influenza | MDVI, LLC | Completed | No outcome recorded |
| Phase 220 trials | ||||||
| Phase 2 | NCT06488300 | Jul 2024 → Jan 2027 expected | respiratory syncytial virus infectious disease | University of Oxford | Recruiting | No outcome recorded |
| Phase 2 | NCT05648448 | Feb 2023 → Jan 2027 expected | influenza | University of Oxford | Recruiting | No outcome recorded |
| Phase 2 | NCT04940871 | Nov 2021 | COVID-19 | University of Pecs | Terminated | No outcome recorded |
| Phase 2 | NCT04918927 | Oct 2021 → Mar 2023 | COVID-19 | Coordinación de Investigación en Salud, Mexico | Completed | No outcome recorded |
| Phase 2 | NCT05041907 | Sep 2021 → Jan 2027 expected | COVID-19 | University of Oxford | Recruiting | No outcome recorded |
| Phase 2 | NCT04907682 | Jul 2021 → Nov 2022 | Lassa fever | Bernhard Nocht Institute for Tropical Medicine | Completed | No outcome recorded |
| Phase 2 | NCT04475991 | Jul 2021 → Mar 2022 | COVID-19 | Hospital General de México Dr. Eduardo Liceaga | Terminated | No outcome recorded |
| Phase 2 | NCT05184127 | Apr → Sep 2021 | COVID-19 | National Research Center - Institute of Immunology Federal Medical-Biological Agency of Russia | Completed | No outcome recorded |
| Phase 2 | NCT04448119 | Oct 2020 → Oct 2021 | COVID-19 | Appili Therapeutics Inc. | Terminated | No outcome recorded |
| Phase 2 | NCT04499677 | Sep 2020 → Dec 2021 | COVID-19 | University College, London | Completed | No outcome recorded |
| Phase 2 | NCT04532931 | Sep 2020 → Aug 2021 | COVID-19 | Shin Poong Pharmaceutical Co. Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT04387760 | Aug 2020 → Mar 2021 | COVID-19 | Royal College of Surgeons in Ireland - Medical University of Bahrain | Completed | No outcome recorded |
| Phase 2 | NCT04445467 | Jul 2020 → Nov 2021 | COVID-19 | Bayside Health | Unknown | No outcome recorded |
| Phase 2 | NCT04346628 | Jul 2020 → Apr 2021 | COVID-19 | Stanford University | Completed | No outcome recorded |
| Phase 2 | NCT04358549 | Apr → Sep 2020 | COVID-19 | Fujifilm Pharmaceuticals U.S.A., Inc. | Completed | No outcome recorded |
| Phase 2 | NCT03394209 | Feb 2018 → Feb 2019 | influenza | Capital Medical University | Completed | No outcome recorded |
| Phase 2 | NCT02739477 | Apr → Aug 2016 | Ebola hemorrhagic fever | French National Institute of Health and Medical Research | Terminated | No outcome recorded |
| Phase 2 | NCT02329054 | Dec 2014 → May 2015 | Ebola hemorrhagic fever | French National Institute of Health and Medical Research | Completed | No outcome recorded |
| Phase 2 | NCT02662855 | Nov 2014 → Apr 2015 | Ebola hemorrhagic fever | Beijing Institute of Pharmacology and Toxicology | Completed | No outcome recorded |
| Phase 2 | NCT01068912 | Feb 2010 → Apr 2012 | influenza | MDVI, LLC | Completed | No outcome recorded |
| Phase 2/36 trials | ||||||
| Phase 2/3 | NCT06212336 | May 2025 → Jun 2027 expected | Lassa fever | Irrua Specialist Teaching Hospital | Recruiting | No outcome recorded |
| Phase 2/3 | NCT04464408 | Jul 2020 → Aug 2021 | COVID-19 | King Abdullah International Medical Research Center | Completed | No outcome recorded |
| Phase 2/3 | NCT04402203 | May → Jul 2020 | COVID-19 | Bangladesh Medical Research Council (BMRC) | Unknown | No outcome recorded |
| Phase 2/3 | NCT04434248 | Apr → Jul 2020 | COVID-19 | Chromis LLC | Unknown | No outcome recorded |
| Phase 2/3 | NCT04351295 | Apr → Sep 2020 | COVID-19 | Tanta University | Completed | No outcome recorded |
| Phase 2/3 | NCT04319900 | Mar → Apr 2020 | COVID-19 | Beijing Chao Yang Hospital | Unknown | No outcome recorded |
| Phase 314 trials | ||||||
| Phase 3 | NCT04818320 | Feb → Jul 2021 | COVID-19 | Penang Hospital, Malaysia | Completed | No outcome recorded |
| Phase 3 | NCT04600895 | Nov 2020 → Oct 2021 | COVID-19 | Appili Therapeutics Inc. | Completed | No outcome recorded |
| Phase 3 | NCT04613271 | Oct 2020 → Oct 2021 | COVID-19 | Ina-Respond | Completed | No outcome recorded |
| Phase 3 | NCT05014373 | Oct 2020 → Aug 2021 | COVID-19 | University of the Philippines | Unknown | No outcome recorded |
| Phase 3 | NCT04600999 | Oct → Dec 2020 | COVID-19 | University of Pecs | Completed | No outcome recorded |
| Phase 3 | NCT04529499 | Aug 2020 → Jan 2021 | COVID-19 | Dr. Reddy's Laboratories Limited | Terminated | No outcome recorded |
| Phase 3 | NCT04425460 | Jun → Aug 2020 | COVID-19 | Zhejiang Hisun Pharmaceutical Co. Ltd. | Unknown | No outcome recorded |
| Phase 3 | NCT04542694 | May → Aug 2020 | COVID-19 | Promomed, LLC | Completed | No outcome recorded |
| Phase 3 | NCT04501783 | May → Jul 2020 | COVID-19 | R-Pharm | Completed | No outcome recorded |
| Phase 3 | NCT04411433 | May → Dec 2020 | COVID-19 | Ministry of Health, Turkey | Unknown | No outcome recorded |
| Phase 3 | NCT04373733 | May 2020 → Jun 2021 | COVID-19 | Chelsea and Westminster NHS Foundation Trust | Completed | No outcome recorded |
| Phase 3 | NCT04349241 | Apr → Jun 2020 | COVID-19 | Ain Shams University | Completed | No outcome recorded |
| Phase 3 | NCT04558463 | Apr → Sep 2020 | COVID-19 | Indonesia University | Unknown | No outcome recorded |
| Phase 3 | NCT04336904 | Mar → Jul 2020 | COVID-19 | Giuliano Rizzardini | Unknown | No outcome recorded |
| Phase 42 trials | ||||||
| Phase 4 | NCT05502081 | Sep → Dec 2022 | COVID-19 | Mansoura University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT04359615 | Apr → May 2020 | COVID-19 | Shahid Beheshti University of Medical Sciences | Unknown | No outcome recorded |
| Phase not applicable3 trials | ||||||
| — | NCT04392973 | May 2020 → Jan 2021 | COVID-19 | King Abdullah International Medical Research Center | Completed | No outcome recorded |
| — | NCT04333589 | Apr → Jun 2020 | COVID-19 | Peking University First Hospital | Unknown | No outcome recorded |
| — | NCT04376814 | Mar → Apr 2020 | COVID-19 | Baqiyatallah Medical Sciences University | Completed | No outcome recorded |
Also used as a comparator or background therapy in 15 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT05940545 Comparator | Jul → Sep 2023 | Crimean-Congo hemorrhagic fever | Liverpool School of Tropical Medicine | Unknown | No outcome recorded |
| Phase 1/2 | NCT04715360 Background | Dec 2020 → Nov 2021 | COVID-19, acute respiratory distress syndrome | Hayandra Peduli Foundation | Unknown | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT06860334 Comparator | Jul 2025 → Dec 2027 expected | Crimean-Congo hemorrhagic fever | Liverpool School of Tropical Medicine | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT04718285 Background | May 2021 → May 2022 | COVID-19 | Bahçeşehir University | Unknown | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT04828564 Comparator | Apr → Sep 2021 | COVID-19 | The Scientific and Technological Research Council of Turkey | Unknown | No outcome recorded |
| Phase 39 trials | ||||||
| Phase 3 | NCT05279235 Comparator | Mar → Dec 2022 | — | Shanghai Vinnerna Biosciences Co., Ltd. | Terminated | No outcome recorded |
| Phase 3 | NCT05185284 Comparator | Aug → Dec 2021 | COVID-19 | Promomed, LLC | Completed | No outcome recorded |
| Phase 3 | NCT05187793 Background | Jul 2021 → Oct 2022 | COVID-19 | R-Pharm | Unknown | No outcome recorded |
| Phase 3 | NCT04784559 Comparator | Jun 2021 → Mar 2023 | COVID-19 | PharmaMar | Terminated | No outcome recorded |
| Phase 3 | NCT05417997 Background | May → Dec 2021 | COVID-19, bacterial pneumonia, influenza | RAAS Nutritionals, LLC | Completed | No outcome recorded |
| Phase 3 | NCT04694612 Comparator | Jan → Mar 2021 | COVID-19 | Nepal Health Research Council | Unknown | No outcome recorded |
| Phase 3 | NCT04981379 Comparator | Nov 2020 → Jan 2021 | COVID-19 | Health Institutes of Turkey | Completed | No outcome recorded |
| Phase 3 | NCT02026349 Comparator | Jan 2014 → Mar 2015 | influenza | MDVI, LLC | Completed | No outcome recorded |
| Phase 3 | NCT02008344 Comparator | Dec 2013 → Jan 2015 | influenza | MDVI, LLC | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT04310228 Comparator | Mar → May 2020 | COVID-19 | Peking University First Hospital | Unknown | No outcome recorded |
Evidence & citations 10 cited values
Every value below carries the sentence it was read from. 65 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Favipiravir | “standard therapy which included symptomatic treatment as well as etiotropic drugs such as Favipiravir, Umifenovir, Remdesivir, convalescent plasma and interferon α-2b.” NCT05184127 ↗61“Favipiravir, 200 mg, film coated tablets” NCT05187793 ↗ |
| Known as | AVIGAN | “Favipiravir (or Avigan) 1800 mg tablet 2x a day on Day 1 then 800 mg 2x a day from Day 2 to maximum of Day 14” NCT05014373 ↗4“Patient received avigan 2x1,600 mg for a day, followed by 2x600 mg for five consecutive days.” NCT04715360 ↗ “Name: AVIGAN Generic name: Favipiravir” NCT04600999 ↗ |
| Known as | Avigan (favipiravir) | “Avigan® (favipiravir)” NCT04558463 ↗ |
| Known as | Favicovir | “Montelukast plus Favicovir (Favipiravir)” NCT04718285 ↗ |
| Known as | Favipira | “Favipiravir 200 mg (Favipira) tablet will be given orally.” NCT04402203 ↗ |
| Known as | FPV | “Favipiravir (FPV) has shown to be capable to reduce the time of viral clearance by half.” NCT04475991 ↗ |
| Known as | T-705 | “Favipiravir, previously known as T-705, is a prodrug of a purine nucleotide, favipiravir ribofuranosyl-5'-triphosphate.” NCT04359615 ↗ |
| Action | Inhibit | “a viral RNA-dependent RNA polymerase inhibitor.” NCT03394209 ↗ |
| Modality | Small molecule | “pyrazine carboxamide derivative (6-fluoro-3-hydroxy-2-pyrazinecarboxamide)” NCT04349241 ↗ |
| Route | Oral | “Oral Favipiravir Exposure and Pharmacodynamic Effects in Adult Outpatients With Acute Influenza.” PMID 37739792 ↗ Aug 2024 |